Pearl Therapeutics Secures $65,000,000 Series D Round

  • Feed Type
  • Date
  • Company Name
    Pearl Therapeutics
  • Mailing Address
    200 Saginaw Drive Redwood City, CA 94063
  • Company Description
    Pearl Therapeutics is focused on developing a pipeline of novel and
    superior products for chronic respiratory disorders, providing patients
    with advanced therapeutic options in familiar and well accepted dosage
    forms. The company has licensed advanced particle technology from Nektar
    Therapeutics (Nasdaq: NKTR) for developing a series of products in selected
    therapeutic fields.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from this financing will be used by Pearl to start Phase 3 for PT003, Pearl’s lead candidate product comprised of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI).
  • M&A Terms
  • Venture Investor
    Vatera Healthcare Partners
  • Venture Investor
    5AM Ventures
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Clarus Ventures

Trending on Xconomy